ALIMERA SCIENCES, INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 12 rows in 2017. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2017-06-22: Reporting owner Halak Brian K; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-22: Reporting owner Brooks Mark J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-22: Reporting owner Pizzo Peter J. III; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2017-06-22: Reporting owner Roberts Calvin W.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2017-06-22 | Halak Brian K Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-26 | |
| 2017-06-22 | Brooks Mark J Director | 4 | Stock Option (Right to Buy) Derivative · Indirect · See FN | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-06-22 | Pizzo Peter J. III Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-06-22 | Roberts Calvin W. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-06-22 | Kong Garheng Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-06-22 | BRADLEY GLEN Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-06-22 | Largent James R Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $1.37 exercise price | 2017-06-23 | |
| 2017-01-20 | Green Kenneth Officer (SVP & Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $1.18 exercise price | 2017-01-23 | |
| 2017-01-20 | Myers C. Daniel Director, Officer (CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +425,000 425,000 owned after | $1.18 exercise price | 2017-01-23 | |
| 2017-01-20 | EISWIRTH RICHARD S JR Officer (President and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +325,000 325,000 owned after | $1.18 exercise price | 2017-01-23 | |
| 2017-01-20 | Holland David Officer (SVP of Sales and Marketing) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.18 exercise price | 2017-01-23 | |
| 2017-01-20 | Ashman Philip Officer (SVP, EU Managing Director) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.18 exercise price | 2017-01-23 |